Platelet Dysfunction in Patients With Bleeding Disorder of Unknown Cause (TARGET-BDUC)

November 17, 2026 updated by: Dino Mehic, Medical University of Vienna

Platelet Dysfunction in Bleeding Disorder of Unknown Cause: Novel Diagnostic and Therapeutic Targets of Platelet Dysfunction in Patients With Bleeding Disorder of Unknown Cause - The TARGET-BDUC Study

Bleeding disorder of unknown cause (BDUC) affects people who experience excessive bleeding despite normal routine laboratory tests. Undetected platelet dysfunction may contribute to their bleeding symptoms.

The TARGET-BDUC study aims to investigate platelet function, particularly the formation of procoagulant platelets, and identify underlying mechanisms and potential diagnostic biomarkers.

The study will include 100 patients with BDUC and 30 healthy controls. Advanced platelet function testing, imaging, and proteomic and lipidomic analyses will be performed.

The findings may improve the diagnosis of BDUC and help identify patients who could benefit from targeted treatment.

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Study Type

Observational

Enrollment (Estimated)

130

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Sampling Method

Probability Sample

Study Population

This single-center observational study will recruit 100 patients with bleeding disorder of unknown cause (BDUC) from the Vienna Bleeding Biobank (VIBB) at the Medical University of Vienna and 30 age- and sex-matched healthy controls from the Vienna Bleeding Study (VIBS).

Patients with BDUC will have a clinically relevant bleeding phenotype despite normal conventional hemostatic testing, including light transmission aggregometry, and at least one prolonged PFA-100 closure time.

All participants will undergo comprehensive platelet function testing. For detailed mechanistic and multi-omics analyses, 30 BDUC patients with reduced procoagulant platelet formation, 30 BDUC patients with normal procoagulant platelet formation, and 30 healthy controls will be selected.

An exploratory substudy will assess platelet function before and after desmopressin (DDAVP) administration in 10 patients with BDUC and 5 comparison participants receiving DDAVP as part of routine clinical care.

Description

Inclusion Criteria:

Patients with bleeding disorder of unknown cause (BDUC):

  • Age ≥16 years.
  • Diagnosis of BDUC following comprehensive hemostatic evaluation without identification of a specific bleeding disorder.
  • Abnormal ISTH Bleeding Assessment Tool (ISTH-BAT) score (≥4 in men or ≥6 in women).
  • Normal light transmission aggregometry (LTA).
  • Prolonged PFA-100 closure time in at least one cartridge (collagen/epinephrine or collagen/ADP).
  • Written informed consent.

Healthy controls:

  • Age ≥16 years.
  • No history of abnormal bleeding or thrombosis.
  • Age- and sex-matched to the BDUC study population.
  • Written informed consent.

Exclusion Criteria:

  • Pregnancy.
  • Recent surgery or infection.
  • Active malignancy.
  • Thrombocytopenia (platelet count <100 × 10⁹/L).
  • Liver dysfunction (prothrombin time activity <75%).
  • Renal impairment (eGFR <60 mL/min/1.73 m²).
  • Use of anticoagulants, nonsteroidal anti-inflammatory drugs (NSAIDs), or other medications affecting platelet function within 10 days before blood sampling.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: COHORT
  • Time Perspectives: PROSPECTIVE

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Procoagulant Platelet Formation in Patients With BDUC Compared With Healthy Controls
Time Frame: At baseline (single blood sample collected at enrollment; no follow-up assessment).

Procoagulant platelet formation will be quantified by flow cytometry following dual platelet stimulation with TRAP-6 and CRP-XL. Procoagulant platelets will be identified by simultaneous CD62P and lactadherin positivity, indicating platelet activation and phosphatidylserine exposure. The percentage of procoagulant platelets will be compared between patients with bleeding disorder of unknown cause (BDUC) and healthy controls to identify impaired procoagulant platelet responses.

At baseline (single blood sample collected at enrollment; no follow-up assessment).

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Collaborators

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

January 1, 2027

Primary Completion (Estimated)

December 31, 2029

Study Completion (Estimated)

December 31, 2030

Study Registration Dates

First Submitted

October 30, 2026

First Submitted That Met QC Criteria

November 17, 2026

First Posted (Actual)

November 19, 2026

Study Record Updates

Last Update Posted (Actual)

November 19, 2026

Last Update Submitted That Met QC Criteria

November 17, 2026

Last Verified

October 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • KLP1389626
  • KLP1389626 (Other Grant/Funding Number: Austrian Science Fund (FWF))

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.